A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
NCT ID: NCT01989754
Last Updated: 2018-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
5813 participants
INTERVENTIONAL
2014-01-16
2017-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a 2-week screening period and a double-blind treatment period lasting between 78 and 156 weeks; study completion is targeted for when the last subject randomized has approximately 78 weeks of follow-up or when 688 major adverse cardiovascular events are accumulated between CANVAS and CANVAS-R. A total of 5,700 participants are targeted to be recruited into the study. Participants can be either drug naïve to antihyperglycemic agents, using monotherapy, or using combination of antihyperglycemic therapy for the control of blood glucose levels.
The completion target was reached in February 2017.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Canagliflozin (JNJ-28431754)
Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
Canagliflozin, 100 mg
One 100 mg capsule taken orally (by mouth) once daily
Canagliflozin, 300 mg
One 300 mg capsule taken orally (by mouth) once daily
Placebo
Each patient will receive placebo (inactive medication) once daily.
Placebo
One placebo capsule taken orally (by mouth) once daily for 156 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
One placebo capsule taken orally (by mouth) once daily for 156 weeks
Canagliflozin, 100 mg
One 100 mg capsule taken orally (by mouth) once daily
Canagliflozin, 300 mg
One 300 mg capsule taken orally (by mouth) once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have inadequate diabetes control (as defined by glycosylated hemoglobin level \>=7.0% to \<=10.5% at screening)
* Greater than or equal to (\>=) 30 yrs old with history of cardiovascular (CV) event, or \>= 50 yrs old with high risk of CV events
* Must be either not on antihyperglycemic agents (AHA) therapy, or on AHA monotherapy, or combination AHA therapy with any approved agent for the control of blood glucose levels.
Exclusion Criteria
* History of one or more severe hypoglycemic episode within 6 months before screening
* History of hereditary glucose-galactose malabsorption or primary renal glucosuria
* Ongoing, inadequately controlled thyroid disorder
* Renal disease that required treatment with immunosuppressive therapy or a history of chronic dialysis or renal transplant
* Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 3 months before screening.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The George Institute for Global Health, Australia
OTHER
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Little Rock, Arkansas, United States
Carmichael, California, United States
Concord, California, United States
Pismo Beach, California, United States
Roseville, California, United States
Thousand Oaks, California, United States
Denver, Colorado, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
Opa-locka, Florida, United States
Orlando, Florida, United States
Palm Harbor, Florida, United States
Tampa, Florida, United States
Meridian, Idaho, United States
Chicago, Illinois, United States
Valparaiso, Indiana, United States
Topeka, Kansas, United States
Louisville, Kentucky, United States
Mandeville, Louisiana, United States
Metairie, Louisiana, United States
Elkridge, Maryland, United States
Flint, Michigan, United States
Picayune, Mississippi, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Washington, Missouri, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Cornelius, North Carolina, United States
Hickory, North Carolina, United States
Mooresville, North Carolina, United States
Canal Fulton, Ohio, United States
Franklin, Ohio, United States
Mason, Ohio, United States
Oklahoma City, Oklahoma, United States
Beaver, Pennsylvania, United States
Levittown, Pennsylvania, United States
Norristown, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Tipton, Pennsylvania, United States
Greer, South Carolina, United States
Jefferson City, Tennessee, United States
Austin, Texas, United States
Pearland, Texas, United States
Bountiful, Utah, United States
Draper, Utah, United States
Salt Lake City, Utah, United States
West Jordan, Utah, United States
South Burlington, Vermont, United States
Falls Church, Virginia, United States
Norfolk, Virginia, United States
Virginia Beach, Virginia, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Buenos Aires, , Argentina
Ciudad de Buenos Aires, , Argentina
Córdoba, , Argentina
Mar del Plata, , Argentina
Morón, , Argentina
Rosario, , Argentina
Zarate, Buenos Aires, , Argentina
Box Hill, , Australia
Cairns, , Australia
Daw Park, , Australia
Freemantle, , Australia
Liverpool, , Australia
Melbourne, , Australia
Newcastle, , Australia
Sherwood, , Australia
Sydney, , Australia
Tasmania, , Australia
Woden, , Australia
Woolloongabba, , Australia
Bonheiden, , Belgium
Bruges, , Belgium
Edegem, , Belgium
Ghent, , Belgium
La Louvière, , Belgium
Leuven, , Belgium
Liège, , Belgium
Liÿge, , Belgium
Merksem, , Belgium
Ransart, , Belgium
Roeselare, , Belgium
Tessenderlo, , Belgium
Belém, , Brazil
Belo Horizonte, , Brazil
Campinas, , Brazil
Caxias do Sul, , Brazil
Curitiba, , Brazil
Fortaleza, , Brazil
Mogi das Cruzes, , Brazil
Passo Fundo, , Brazil
Porto Alegre, , Brazil
Rio de Janeiro, , Brazil
São José do Rio Preto, , Brazil
São Paulo, , Brazil
Coquitlam, British Columbia, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Guelph, Ontario, Canada
Mississauga, Ontario, Canada
Oshawa, Ontario, Canada
Sarnia, Ontario, Canada
Thornhill, Ontario, Canada
Toronto, Ontario, Canada
Laval, Quebec, Canada
Lévis, Quebec, Canada
Québec, Quebec, Canada
Saint Marc Des Carriéres, Quebec, Canada
Sherbrooke, Quebec, Canada
Westmont, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Baotou, , China
Beijing, , China
Hangzhou, , China
Jinan, , China
Shenyang, , China
Wuxi, , China
Beroun, , Czechia
Ostrava, , Czechia
Pilsen, , Czechia
Prague, , Czechia
Znojmo, , Czechia
Amiens, , France
Bois-Guillaume, , France
Bordeaux, , France
Dijon, , France
Grenoble, , France
La Rochelle, , France
Le Creusot, , France
Narbonne, , France
Paris, , France
Poitiers, , France
Aschaffenburg, , Germany
Aßlar, , Germany
Bad Oeynhausen, , Germany
Dortmund, , Germany
Dresden, , Germany
Freiburg im Breisgau, , Germany
Hanover, , Germany
Kassel, , Germany
Mainz, , Germany
Neuwied, , Germany
Saarbrücken, , Germany
Villingen-Schwenningen, , Germany
Balatonfüred, , Hungary
Budapest, , Hungary
Dunaújváros, , Hungary
Eger, , Hungary
Kecskemét, , Hungary
Nagykanizsa, , Hungary
Pécs, , Hungary
Székesfehérvár, , Hungary
Szikszó, , Hungary
Szombathely, , Hungary
Zalaegerszeg, , Hungary
*Osenza*, , Italy
Arenzano, , Italy
Bologna, , Italy
Catanzaro, , Italy
Chieri (Torino), , Italy
Florence, , Italy
Messina, , Italy
Milan, , Italy
Napoli, , Italy
Ravenna, , Italy
Roma, , Italy
Sesto San Giovanni (Milano), , Italy
Verona, , Italy
Batu Caves, , Malaysia
George Town, , Malaysia
Ipoh, , Malaysia
Kelantan, , Malaysia
Kota Bharu, , Malaysia
Kuala Lumpur, , Malaysia
Kuching, , Malaysia
Aguascalientes, , Mexico
Celaya, , Mexico
Cuernavaca, , Mexico
Culiacán, , Mexico
Guadalajara, , Mexico
México, , Mexico
Pachuca, , Mexico
Querétaro, , Mexico
San Luis Potosí City, , Mexico
Tampico, , Mexico
Almelo, , Netherlands
Almere Stad, , Netherlands
Amersfoort, , Netherlands
Amsterdam, , Netherlands
Dordrecht, , Netherlands
Eindhoven, , Netherlands
Groningen, , Netherlands
Hardenberg, , Netherlands
Hoogeveen, , Netherlands
Hoogezand, , Netherlands
Kloosterhaar, , Netherlands
Leiden, , Netherlands
Meppel, , Netherlands
Poortvliet, , Netherlands
Rotterdam, , Netherlands
Utrecht, , Netherlands
Velp, , Netherlands
Waalwijk, , Netherlands
Wamel, , Netherlands
Zoetermeer, , Netherlands
Zwijndrecht, , Netherlands
Auckland, , New Zealand
Christchurch, , New Zealand
Newtown, , New Zealand
Palmerston North, , New Zealand
Rotorua, , New Zealand
Tauranga, , New Zealand
Wellington, , New Zealand
Bialystok, , Poland
Bydgoszcz, , Poland
Chrzanów, , Poland
Gdansk, , Poland
Grodzisk Mazowiecki, , Poland
Katowice, , Poland
Krakow, , Poland
Lublin, , Poland
Oświęcim, , Poland
Torun, , Poland
Tychy, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Ponce Pr, , Puerto Rico
Trujillo Alto, , Puerto Rico
Arkhangelsk, , Russia
Barnaul, , Russia
Chelyabinsk, , Russia
Kemerovo, , Russia
Nizhny Novgorod, , Russia
Penza, , Russia
Rostov-on-Don, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Saratov, , Russia
Smolensk, , Russia
Syktyvkar, , Russia
Tyumen, , Russia
Vsevolzhsk, , Russia
Yaroslavl, , Russia
Ansan, , South Korea
Bucheon-si, , South Korea
Busan, , South Korea
Changwon, , South Korea
Cheongju-si, , South Korea
Daegu, , South Korea
Gyeonggi-do, , South Korea
Iksan, , South Korea
Incheon, , South Korea
Jeonju, , South Korea
Seongnam-si, , South Korea
Seoul, , South Korea
Suwon, , South Korea
Ulsan, , South Korea
Wŏnju, , South Korea
A Coruña, , Spain
Alcalá de Henares, , Spain
Alicante, , Spain
Almería, , Spain
Alzira, , Spain
Barcelona, , Spain
Ciudad Real, , Spain
Córdoba, , Spain
Ferrol, , Spain
Figueres, , Spain
Galdakao, , Spain
Madrid, , Spain
Málaga, , Spain
Móstoles, , Spain
Palma de Mallorca, , Spain
Sabadell, , Spain
San Sebastián de los Reyes, , Spain
Sant Joan d'Alacant, , Spain
Santa Cruz de Tenerife, , Spain
Santiago de Compostela, , Spain
Segovia, , Spain
Seville, , Spain
Valencia, , Spain
Viladecans, , Spain
Borås, , Sweden
Gothenburg, , Sweden
Helsingborg, , Sweden
Karlstad, , Sweden
Linköping, , Sweden
Lund, , Sweden
Malmo, , Sweden
Stockholm, , Sweden
Uddevalla, , Sweden
Uppsala, , Sweden
Vällingby, , Sweden
Västra Frölunda, , Sweden
Kaohsiung County, , Taiwan
Taichung, , Taiwan
Tainan City, , Taiwan
Taipei, , Taiwan
Tiachung, , Taiwan
Xindian, , Taiwan
Cherkasy, , Ukraine
Chernivtsy, , Ukraine
Dnipropetrovsk, , Ukraine
Ivan-Frankivsk, , Ukraine
Ivano-Frankivsk, , Ukraine
Kharkiv, , Ukraine
Kiev, , Ukraine
Kyiv, , Ukraine
Lviv, , Ukraine
Odesa, , Ukraine
Poltava, , Ukraine
Sumy, , Ukraine
Ternopil, , Ukraine
Uzhhorod, , Ukraine
Vinnitsa, , Ukraine
Vinnytsia, , Ukraine
Zaporizhzhia, , Ukraine
Zaporizhzhya, , Ukraine
Addlestone, , United Kingdom
Belfast, , United Kingdom
Birmingham, , United Kingdom
Blackburn, , United Kingdom
Bristol, , United Kingdom
Bury St Edmunds, , United Kingdom
Chesterfield, , United Kingdom
Derby, , United Kingdom
Doncaster, , United Kingdom
Ipswich, , United Kingdom
Leicester, , United Kingdom
Liverpool, , United Kingdom
Manchester, , United Kingdom
Salford, , United Kingdom
Taunton, , United Kingdom
Torquay, , United Kingdom
Truro, , United Kingdom
Wellingborough, , United Kingdom
Welwyn Garden City, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Januzzi JLJ, Sattar N, Vaduganathan M, Magaret CA, Rhyne RF, Liu Y, Masson S, Butler J, Hansen MK. A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease. Cardiovasc Diabetol. 2025 May 15;24(1):213. doi: 10.1186/s12933-025-02779-5.
Doi Y, Hamano T, Yamaguchi O, Isaka Y. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. Blood Adv. 2025 Jul 8;9(13):3202-3212. doi: 10.1182/bloodadvances.2025016320.
Nguyen TN, Yu J, Perkovic V, Jardine M, Mahaffey KW, Chow CK, Arnott C, Lindley RI. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025 Jun;73(6):1787-1796. doi: 10.1111/jgs.19444. Epub 2025 Mar 19.
Vaduganathan M, Cannon CP, Jardine MJ, Heerspink HJL, Arnott C, Neuen BL, Sarraju A, Gogate J, Seufert J, Neal B, Perkovic V, Mahaffey KW, Kosiborod MN. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial. Eur J Heart Fail. 2024 Sep;26(9):1967-1975. doi: 10.1002/ejhf.3292. Epub 2024 Jun 26.
Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
Sharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL, Arnott C, Perkovic V, Mahaffey KW. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19.
Yu J, Sweeting AN, Gianacas C, Houston L, Lee V, Fletcher RA, Perkovic V, Li Q, Neuen BL, Berwanger O, Heerspink HJL, de Zeeuw D, Arnott C. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2023 Dec;25(12):3724-3735. doi: 10.1111/dom.15267. Epub 2023 Sep 6.
Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 Jul 4;12(13):e028516. doi: 10.1161/JAHA.122.028516. Epub 2023 Jun 22.
Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2940-2949. doi: 10.1210/clinem/dgad249.
Ferrannini G, Pollock C, Natali A, Yavin Y, Mahaffey KW, Ferrannini E. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE. Cardiovasc Diabetol. 2023 Apr 29;22(1):100. doi: 10.1186/s12933-023-01832-5.
Nunes JC, Yu J, Arnott C, Jardine MJ, Perkovic V, Mahaffey KW. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. Diabetes Obes Metab. 2022 Dec;24(12):2459-2464. doi: 10.1111/dom.14832. Epub 2022 Aug 19. No abstract available.
Young TK, Li JW, Kang A, Heerspink HJL, Hockham C, Arnott C, Neuen BL, Zoungas S, Mahaffey KW, Perkovic V, de Zeeuw D, Fulcher G, Neal B, Jardine M. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia. 2021 Nov;64(11):2402-2414. doi: 10.1007/s00125-021-05524-1. Epub 2021 Aug 26.
Yu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovasc Res. 2022 Mar 16;118(4):1103-1114. doi: 10.1093/cvr/cvab128.
Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MD. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021 Apr;8(2):1482-1493. doi: 10.1002/ehf2.13236. Epub 2021 Feb 17.
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21.
Oshima M, Neal B, Toyama T, Ohkuma T, Li Q, de Zeeuw D, Heerspink HJL, Mahaffey KW, Fulcher G, Canovatchel W, Matthews DR, Perkovic V. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. J Am Soc Nephrol. 2020 Oct;31(10):2446-2456. doi: 10.1681/ASN.2019121312. Epub 2020 Jul 21.
Matthews DR, Wysham C, Davies M, Slee A, Alba M, Lee M, Perkovic V, Mahaffey KW, Neal B. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. Diabetes Obes Metab. 2020 Nov;22(11):2199-2203. doi: 10.1111/dom.14143. Epub 2020 Aug 24.
Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. JACC Heart Fail. 2020 Jan;8(1):57-66. doi: 10.1016/j.jchf.2019.08.004. Epub 2019 Oct 29.
Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.
Figtree GA, Radholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.
Zhou Z, Lindley RI, Radholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B. Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.
Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145.
Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-003050-25
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
28431754DIA4003
Identifier Type: OTHER
Identifier Source: secondary_id
CR102647
Identifier Type: -
Identifier Source: org_study_id